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Abstract 
BACKGROUND: Clostridium difficile is a major nosocomial pathogen. In Europe, this bacterium is mostly 
characterised by PCR ribotyping. Most of the Clostridium difficile infections (CDI) are treated with vancomycin or 
metronidazole, although prolonged antibiotic use is considered as one of the main risk factors for CDI. 
AIM: This study aimed to detect the presence of various C. difficile ribotypes in hospitalised patients and to 
investigate their toxigenicity and antibiotic susceptibility. 
MATERIAL AND METHODS: All stool samples obtained from each patient were inoculated on Columbia blood 
agar and cycloserine cefoxitine fructose agar (CCFA) for isolation of C. difficile. Glutamate dehydrogenase and 
toxins A and B were investigated by immunochromatographic tests. Final confirmation of the isolates was 
performed by Vitek 2 and MALDI-TOF. A total of 21 isolates were collected for further investigation. PCR 
ribotyping was performed as described by Janezic and Rupnik. PCR ribotype profiles were analysed using 
software (Bionumerics, Applied Maths). Antibiotic susceptibility was determined by E-tests for metronidazole, 
vancomycin, tetracycline, clindamycin, erythromycin, imipenem, ciprofloxacin and moxifloxacin. 
RESULTS: About 48% of C. difficile isolates belonged to ribotype 001/072. So, this ribotype was the most 
common ribotype in this study. The remaining 52% of C. difficile isolates consisted of 10 different ribotypes: 017, 
SLO 160, SLO 187, SLO 120, 255/258, 014/020, 046, 002, 070 and 027. Furthermore, 20 (95.2 %) out of 21 
isolates of C. difficile were toxigenic. Toxins A and B were detected simultaneously in 90.5 % of C. difficile 
isolates. Two isolates from the ribotype 017 were toxin B positive only. Treatments with any of the following 
antimicrobials: clindamycin, erythromycin, ciprofloxacin and moxifloxacin (as well as many other antibiotics), could 
be a risk factor for CDI due to the high resistance of the strains in this study. About 90% of the strains from the 
most common ribotype 001/072 have MICs for clindamycin and erythromycin > 256 µg/ml.  
CONCLUSION: All strains isolated are highly resistant to ciprofloxacin. All strains were susceptible to vancomycin 
(median MIC was 0.63 µg/ml) and metronidazole (median MIC was 0.084 µg/ml), so these two antimicrobials 
remain optimal treatment option for CDI. 
 
 
 
 
 
Introduction 
 
Clostridium difficile is one of the most 
common causes of infections in hospitalised patients, 
especially in those with long term hospital stay [1], [2]. 
Although in many underdeveloped countries, 
Clostridium difficile infection (CDI) was under-
diagnosed for a very long time, during the last decade, 
a significant increase in its prevalence was detected 
[3]. C.difficile infection (CDI) can turn even into 
hospital outbreak very frequently [4].  
Many typing methods are involved in the 
investigation of the mode of spreading of CDI, but 
molecular methods are used almost exclusively, due 
to their higher discriminative power [5]. PCR 
ribotyping is the most widely used typing method for 
C. difficile in Europe, although some other 
sequencing-based molecular methods are used in 
many other countries worldwide [6]. PCR ribotyping 
was also used for characterisation of the hypervirulent 
C. difficile strains that have caused a large outbreak in 
Canada in 2002 [6]. Since 2005, the most frequent 
hypervirulent C. difficile strain (027/NAP1/BI) has 
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been identified in many patients from the USA and 
Europe [7]. Ribotype 027 is known as a strain which 
produces toxins A, B and binary toxin, as well as a 
strain with the increased ability for sporulation and 
high antimicrobial resistance [9]. In recent years some 
other hypervirulent strains, like ribotypes 017 and 078, 
have also emerged. Those two ribotypes have been 
involved in many serious outbreaks recently, which 
were quite rare in the past [7], [8], [9], [10].  
Metronidazole and vancomycin are the most 
effective antimicrobial agents for the effective 
treatment of CDI so far. In the last decade, the 
emergence of reduced susceptibility to both of these 
drugs has been reported [11]. It is crucial to monitor 
the susceptibility of C. difficile isolates to antimicrobial 
agents, not only for selecting the optimal treatment 
option but also for risk assessment of acquiring CDI in 
the future. It is well known that using many of the 
broad-spectrum antimicrobials is a major risk factor for 
acquiring CDI like antibiotic-associated diarrhoea or 
pseudomembranous colitis [1]. 
This study aimed to detect the presence of C. 
difficile ribotypes in hospitalised patients and to 
investigate their antibiotic susceptibility and their 
toxigenicity.  
 
 
Material and Methods 
 
A group of 21 strains of C. difficile were 
isolated from stool samples obtained from patients 
with symptoms of CDI, hospitalised in different clinics 
within the Mother Theresa Clinical Centre in Skopje, 
Macedonia, in the period from 2016 to 2018. All stool 
samples were tested for glutamate dehydrogenase 
(GDH) and both C.difficile toxins: A and B, with 
immunochromatographic tests (Mascia Brunelli). Both 
of these quick tests were performed according to the 
manufacturer’s instructions. The stool samples were 
also inoculated on selective CCFA agar (Oxoid) and 
incubated for 48 hours in an anaerobic atmosphere. 
At the same time, an alcohol shock test was 
performed with subsequent inoculation on Columbia 
agar (Oxoid) and incubation under the same 
conditions. Clostridium difficile colonies were identified 
by their typical appearance and smell. They were 
further microscopically confirmed by Gram staining. 
Final confirmation was performed by Vitek 2 
(Biomerieux) and MALDI-TOF (Bruker). The 21 
Clostridium difficile isolates were collected for their 
further typing and antimicrobial susceptibility testing.  
 
PCR Ribotyping 
 As a molecular method, PCR ribotyping is 
based on the amplification of intergenic spacer region 
(ITS) between 16S and 23S rDNA and was performed 
as described by Janezic and Rupnik [12], [13[. PCR 
ribotype profiles of C. difficile isolates were analysed 
by software (Bionumerics, Applied Maths). 
 
Antimicrobial Susceptibility Testing  
 Antibiotic susceptibility of all C. difficile 
isolates was investigated through the determination of 
the minimal inhibitory concentrations (MICs) obtained 
by performing the E test (Biomerieux). One McFarland 
turbidity standard bacteria suspension was prepared 
and inoculated on Mueller-Hinton agar supplemented 
with 5% sheep blood. Antimicrobial strips 
(Biomerieux) were applied at every single plate, and 
they were incubated at the same conditions as for the 
primary isolation. For that purpose, the following 
antimicrobial agents were used: metronidazole 0.016 - 
256 µg/ml, vancomycin 0.016 - 256 µg/ml, tetracycline 
0.016 - 256 µg/ml, clindamycin 0.016 – 256 µg/ml, 
erythromycin 0.016 - 256 µg/ml, imipenem 0.002 - 32 
µg/ml, ciprofloxacin 0.002-32 µg/ml and moxifloxacin 
0.002-32 µg/ml. The susceptibility of the isolates was 
analysed according to CLSI M100-S25 and EUCAST 
v. 8.0, 2018.  
Table 1: Interpretation criteria for antimicrobial susceptibility of 
C. difficile isolates 
 VAN** MTZ** TC* EM* CM* CI* MX* IP* 
 S (µg/ml) ≤ 2 ≤ 2 ≤ 4 - ≤ 2 ≤ 2 ≤ 2 ≤ 4 
 I (µg/ml) - - 8 - 4 4 4 8 
 R (µg/ml) > 2 > 2 ≥ 16 ≥8 ≥ 8 ≥8 ≥ 8 ≥ 16 
*Interpretation based on CLSI M100-S25; **Interpretation based on The European 
Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of 
MICs and zone diameters. Version 8.0, 2018.  
 
Chi-square and Fisher’s exact tests were 
used for testing the differences between proportions, 
and p-value less than 0.05 was considered statistically 
significant.  
 Isolation of the strains, toxins determination, 
Vitek 2 confirmations and antimicrobial susceptibility 
tests were performed at the Institute of Microbiology 
and Parasitology, Medical Faculty Skopje, Macedonia. 
MALDI-TOF confirmations and PCR ribotyping were 
performed at the National Laboratory of Health, 
Environment and Food in Maribor, Slovenia. 
 
 
Results  
 
During the study period, 21 C. difficile isolates 
were obtained from hospitalised patients from 7 to 80 
years of age. 16 out of 21 C. difficile isolates were 
detected in old patients at the age above 60. 13 (62%) 
of the patients were female. All isolates were 
distributed in four different clinics. The total number of 
C. difficile isolates belonged to 11 PCR ribotypes 
(Table 2 and Figure 1).  
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Table 2: Distribution of Clostridium difficile ribotypes 
Clinic  11 different 
C. difficile ribotypes 
Number of particular 
C. difficile ribotype 
Toxins in 
C. difficile ribotypes 
Clinic for pediatric 
diseases  
001/072 1 A and B 
002 1 A and B 
SLO 120 1 A and B 
 
Clinic for internal diseases 
001/072 3 A and B 
014/020 1 A and B 
SLO160 1 A and B 
255/258 1 A and B 
Surgery clinic with ICU 001/072 5 A and B 
017 1 B only 
 
 
Clinic for infectious 
diseases  
001/072 1 A and B 
017 1 B only 
027 1 A and B 
046 1 None 
070 1 A and B 
SLO 187 1 A and B 
ICU- Intensive care unit. 
 
The relatedness of C. difficile isolates is 
shown on the dendrogram in Figure 1. It presents the 
similarity of the band's distribution after the 
electrophoresis. 
 
Figure 1: Dendrogramic representation of the twenty-one isolate of 
Clostridium difficile characterised by PCR ribotyping 
 
Antimicrobial susceptibility of the isolates can 
be observed by comparing the MICs from Table 3 to 
the interpretation criteria shown in Table 1. 
Table 3: Minimal inhibitory concentrations (µg/ml) of the eight 
antimicrobials towards the isolates of Clostridium difficile 
C. difficile 
Ribotype 
Mtz Van Tc Cm Em Ip Ci Mx 
001/072 0.047 0.75 1.5 > 256 > 256 > 32 > 32 > 32 
001/072 < 0.016 1 2 > 256 > 256 > 32 > 32 > 32 
001/072 < 0.016 0.38 2 > 256 > 256 > 32 > 32 > 32 
001/072 0.094 0.50 0.047 3 1 4 > 32 0.25 
001/072 0.047 0.50 2 > 256 > 256 6 > 32 > 32 
001/072 0.023 0.38 1.5 > 256 > 256 4 > 32 > 32 
001/072 0.094 0.75 1 > 256 > 256 4 > 32 > 32 
001/072 0.094 1 3 > 256 > 256 6 > 32 > 32 
001/072 0.032 0.50 2 > 256 > 256 4 > 32 > 32 
001/072 < 0.016 0.75 2 > 256 > 256 > 32 > 32 > 32 
002 0.047 0.38 0.094 6 1.5 > 32 > 32 0.5 
014/020 0.094 0.38 0.094 4 0.75 3 >32 0.5 
017 0.032 0.38 8 >256 >256 >32 >32 0.5 
017 0.023 0.75 8 >256 >256 >32 >32 >32 
027 0.047 0.50 0.064 3 >256 >32 >32 >32 
046 0.047 0.38 0.064 >256 >256 4 >32 0.38 
070 0.25 0.75 0.094 6 1 >32 >32 0.5 
SLO120 0.19 0.50 0.125 6 1 4 >32 0.5 
SLO160 0.19 1.5 0.125 12 >256 4 >32 0.5 
SLO187 0.023 0.50 0.064 4 1 4 >32 0.5 
255/258 0.064 0.75 0.094 4 1 3 >32 0.75 
Mtz-Metronidazole; Van-Vancomycin; Tc-Tetracycline; Cm-Clindamycin; Em-Erythromycin; Ip-Imipenem; Ci-
Ciprofloxacin, Mx-Moxifloxacin. 
Discussion  
 
About 76.2% of C. difficile isolates were 
detected in patients above 60 years of age. Older age 
in patients is a statistically significant risk factor for C. 
difficile infection (p < 0.05). The isolation rate of 
Clostridium difficile was not statistically different 
between male and female patients (p > 0.05), which is 
consistent with many other studies [14]. Clostridium 
difficile infection was identified at all clinics included in 
the study. This finding is not unusual since most of the 
patients in these clinics are constantly receiving 
broad-spectrum antibiotics, which is considered as a 
major risk factor for acquiring CDI.  
C. difficile ribotype 001/072 is the most 
frequent PCR ribotype in our patients (p < 0.05). This 
finding is similar to the results obtained in the previous 
study [15]. 50% of C.difficile isolates with this ribotype 
were detected at the Surgery clinic and the Intensive 
care unit related to it. This high percentage of 001/072 
ribotype suggests that it may be an intrahospital 
ribotype of Clostridium difficile at the Surgery clinic. 
But due to the low number of isolates, this suggestion 
should be confirmed with the larger number of isolates 
and by performing additional typing methods in the 
future. Unlike the results obtained in one of our 
neighbouring countries based on the same type of 
investigation [15], [16], where 027 [15] was revealed 
as the most common C. difficile ribotype, in our study 
this ribotype was detected in one patient only.  
All isolates except the one in this study were 
toxigenic. Non-toxigenic strains are not capable of 
causing a symptomatic disease [17]. Both C. difficile 
toxins (A and B) were detected in 90% of isolates. 
Only two isolates belonging to the ribotype 017 were 
toxin B positive, but toxin A negative. Some authors 
have emphasised that toxin B can not only act like 
cytotoxin but also like enterotoxin [18]. So, patients 
infected with C. difficile strains toxin B positive, toxin A 
negative, could be able to develop identical clinical 
symptoms as patients infected with C. difficile toxin A 
and B positive strains [19]. C. difficile strains positive 
for toxin A only has not been confirmed so far [20]. 
Treatments with any of the following 
antimicrobials: clindamycin, erythromycin, 
ciprofloxacin and moxifloxacin, could be a risk factor 
for CDI due to the high resistance of the strains in this 
study. Ninety per cent of the strains from the most 
common ribotype 001/072 have MICs for clindamycin 
and erythromycin > 256 µg/ml. All strains isolated are 
highly resistant to ciprofloxacin. Resistance to 
moxifloxacin is somewhat lower, but it is still very 
common in the most dominant ribotype 001/072. Nine 
out of ten strains are highly resistant to this antibiotic. 
All C. difficile isolates were susceptible to tetracycline 
except two of them belonging to the ribotype 017 
which revealed intermediate susceptibility.  
All strains were susceptible to vancomycin 
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(median MIC was 0.63 µg/ml) and metronidazole 
(median MIC was 0.084 µg/ml), so these two 
antimicrobials remain an optimal treatment option for 
CDI (Table 2). There is an emergence of resistance of 
C. difficile strains to these two antibiotics globally [11], 
so it should be necessary to monitor the susceptibility 
of all the isolates continuously in the future.  
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